Compare Elastic NV (ESTC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Novartis AG — how do they compare? Elastic NV trades at $76.44 (market cap $7.93B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 37.6× Elastic NV's market cap, and Novartis AG pays a 3.02% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | NVS | |
|---|---|---|
Market Cap | $7.93B | $298.18B |
Sector | Technology | Health |
52-Week High | $94.47 | $168.62 |
52-Week Low | $43.30 | $119.31 |
Enterprise Value | $7.15B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic N.V. (ESTC) trades at $75.11, up 7.38% in the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q1 2026 EPS of $0.61 versus $0.561 expected, highlight operational strength. The company announced AI collaborations with OpenAI and AWS security distinctions, driving positive sentiment.
Outlook remains positive due to growth prospects in AI and security, but risks include high valuation multiples and ongoing legal investigations. The stock offers upside to the consensus price target of $74.21, though investors should weigh profitability improvements against competitive pressures.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
